Celcuity (NASDAQ:CELC) Earns Buy Rating from HC Wainwright

Celcuity (NASDAQ:CELC)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $27.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 167.06% from the stock’s previous close.

Separately, Needham & Company LLC lifted their price target on shares of Celcuity from $23.00 to $29.00 and gave the stock a “buy” rating in a research report on Thursday, February 6th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $30.17.

Celcuity Stock Down 1.3 %

Shares of CELC stock opened at $10.11 on Tuesday. Celcuity has a 1 year low of $8.53 and a 1 year high of $22.04. The company has a debt-to-equity ratio of 0.65, a quick ratio of 10.36 and a current ratio of 10.35. The business’s fifty day moving average is $11.18 and its 200-day moving average is $12.91. The stock has a market cap of $375.38 million, a PE ratio of -3.87 and a beta of 0.65.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings results on Monday, March 31st. The company reported ($0.85) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.13). Equities analysts expect that Celcuity will post -2.62 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Celcuity

A number of large investors have recently made changes to their positions in the company. Summit Investment Advisors Inc. grew its position in Celcuity by 49.5% during the 4th quarter. Summit Investment Advisors Inc. now owns 3,421 shares of the company’s stock worth $45,000 after purchasing an additional 1,132 shares in the last quarter. Aquatic Capital Management LLC acquired a new stake in shares of Celcuity in the fourth quarter worth $50,000. The Manufacturers Life Insurance Company purchased a new position in shares of Celcuity during the fourth quarter valued at $142,000. Bleakley Financial Group LLC acquired a new position in Celcuity during the fourth quarter valued at $146,000. Finally, Trexquant Investment LP purchased a new stake in Celcuity in the 4th quarter worth about $152,000. Institutional investors and hedge funds own 63.33% of the company’s stock.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.